Logo-bi
Bioimpacts. 2024;14(1): 27513.
doi: 10.34172/bi.2023.27513
PMID: 38327629
PMCID: PMC10844585
Scopus ID: 85182785633
  Abstract View: 431
  PDF Download: 500

Original Article

Design and computational analysis of an effective multi-epitope vaccine candidate using subunit B of cholera toxin as a build-in adjuvant against urinary tract infections

Maryam Rezaei 1 ORCID logo, Mehri Habibi 1, Parasoo Ehsani 1, Mohammad Reza Asadi Karam 1*, Saeid Bouzari 1* ORCID logo

1 Molecular Biology Department, Pasteur institute of Iran, Tehran, Iran
*Corresponding Authors: Mohammad Reza Asadi Karam , Email: m_asadi12@yahoo.com; Saeid Bouzari , Email: saeidbouzari@yahoo.com

Abstract

Introduction: Urinary tract infection (UTI) is one of the most common infections, usually caused by uropathogenic Escherichia coli (UPEC). However, antibiotics are a usual treatment for UTIs; because of increasing antibiotic-resistant strains, vaccination can be beneficial in controlling UTIs. Using immunoinformatics techniques is an effective and rapid way for vaccine development.
Methods: Three conserved protective antigens (FdeC, Hma, and UpaB) were selected to develop a novel multi-epitope vaccine consisting of subunit B of cholera toxin (CTB) as a mucosal build-in adjuvant to enhance the immune responses. Epitopes-predicted B and T cells and suitable linkers were used to separate them and effectively increase the vaccine's immunogenicity. The vaccine protein's primary, secondary, and tertiary structures were evaluated, and the best 3D model was selected. Since CTB is the TLR2 ligand, molecular docking was made between the vaccine protein and TLR2. Molecular dynamic (MD) simulation was employed to evaluate the stability of the vaccine protein-TLR2 complex. The vaccine construct was subjected to in silico cloning.
Results: The designed vaccine protein has multiple properties in the analysis. The HADDOCK outcomes show an excellent interaction between vaccine protein and TLR2. The MD results confirm the stability of the vaccine protein- TLR2 complex during the simulation. In silico cloning verified the expression efficiency of our vaccine protein.
Conclusion: The results of this study suggest that our designed vaccine protein could be a promising vaccine candidate against UTI, but further in vitro and in vivo studies are needed.
First Name
Last Name
Email Address
Comments
Security code


Abstract View: 431

Your browser does not support the canvas element.


PDF Download: 500

Your browser does not support the canvas element.

Submitted: 06 Jul 2022
Revision: 26 Dec 2022
Accepted: 30 Jan 2023
ePublished: 19 Jul 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)